Multiple compound-related adverse properties contribute to liver injury caused by Endothelin receptor antagonists

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 2, 2015, Pages 281-290

  Kenna, J Gerry ^a   Stahl, Simone H ^b   Eakins, Julie A ^b   Foster, Alison J ^b   Andersson, Linda C ^c   Bergare, Jonas ^c   Billger, Martin ^c   Elebring, Marie ^c   Elmore, Charles S ^c   Thompson, Richard A ^c  

^a Macclesfield   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMBRISENTAN; BILE SALT EXPORT PUMP; BOSENTAN; CYTOCHROME P450; CYTOCHROME P450 3A4; ENDOTHELIN RECEPTOR ANTAGONIST; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; SITAXSENTAN; ABC TRANSPORTER; ABCB11 PROTEIN, HUMAN; ISOXAZOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; P-GLYCOPROTEIN 2; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY BURDEN; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DRUG CLEARANCE; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HYPERTRANSAMINASEMIA; IC50; IN VITRO STUDY; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE VESICLE; MITOCHONDRIAL RESPIRATION; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; TOXIC HEPATITIS; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; CHEMICAL STRUCTURE; DOSE RESPONSE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; EPITHELIUM CELL; METABOLISM; MITOCHONDRION; OXYGEN CONSUMPTION; PHYSIOLOGY;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; ENDOTHELIN RECEPTOR ANTAGONISTS; EPITHELIAL CELLS; HEPATOCYTES; HUMANS; ISOXAZOLES; MITOCHONDRIA; MOLECULAR STRUCTURE; OXYGEN CONSUMPTION; P-GLYCOPROTEINS; PHENYLPROPIONATES; PYRIDAZINES; SULFONAMIDES; THIOPHENES;

EID: 84919740223     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.220491     Document Type: Article

References (34)

1. Brand MD and Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. Biochem J 435:297-312.
2. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, Rosania GR, et al.; International Transporter Consortium (2013) Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther 94:126-141.
3. Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth G, Müller M, Neidhart W, et al. (1994) Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228-235.
4. Croxtall JD and Keam SJ (2008) Ambrisentan. Drugs 68:2195-2204.
5. Dawson S, Stahl S, Paul N, Barber J, and Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40:130-138.
6. Dingemanse J and van Giersbergen PL (2004) Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 43:1089-1115.
7. Eriksson C, Gustavsson A, Kronvall T, and Tysk C (2011) Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis 20:77-80.
8. Erve JC, Gauby S, Maynard JW, Jr, Svensson MA, Tonn G, and Quinn KP (2013) Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. Chem Res Toxicol 26:926-936.
9. Fattinger K, Funk C, PantzeM,Weber C, Reichen J, Stieger B, andMeier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223-231.
10. Foster AJ, Prime LH, Gustafsson F, Temesi DG, Isin EM, Midlöv J, Castagnoli N, Jr, and Kenna JG (2013) Bioactivation of the cannabinoid receptor antagonist rimonabant to a cytotoxic iminium ion metabolite. Chem Res Toxicol 26:124-135.
11. Frampton JE (2011) Ambrisentan. Am J Cardiovasc Drugs 11:215-226.
12. Galiè N, Hoeper MM, Gibbs JSR, and Simonneau G (2011) Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J 37:475-476.
13. Griffith OW and Meister A (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254:7558-7560.
14. Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, and Kenna JG (2014) A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Toxicol Sci 137:189-211.
15. Hartman JC, Brouwer K, Mandagere A, Melvin L, and Gorczynski R (2010) Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 88:682-691.
16. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, and Hoeper MM (2007) Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30:338-344.
17. Kidron H, Wissel G, Manevski N, Häkli M, Ketola RA, Finel M, Yliperttula M, Xhaard H, and Urtti A (2012) Impact of probe compound in MRP2 vesicular transport assays. Eur J Pharm Sci 46:100-105.
18. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, and Chalasani N (2008) Relationship between daily dose of oral medications and idiosyncratic druginduced liver injury: search for signals. Hepatology 47:2003-2009.
19. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, and Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220.
20. Lepist EI, Gillies H, Smith W, Hao J, Hubert C, St. Claire RL, 3rd, Brouwer KR, and Ray AS (2014) Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. PLoS One 9:e87548.
21. Mano Y, Usui T, and Kamimura H (2007) Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos 28:13-18.
22. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, et al. (2009) Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 135:122-129.
23. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, 2nd, Afshari CA, and Hamadeh HK (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci 136:216-241.
24. Nadanaciva S and Will Y (2011) Investigating mitochondrial dysfunction to increase drug safety in the pharmaceutical industry. Curr Drug Targets 12:774-782.
25. Owen K, Cross DM, Derzi M, Horsley E, and Stavros FL (2012) An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension. Regul Toxicol Pharmacol 64:95-103.
26. Park BK, Boobis A, Clarke S, Goldring CEP, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, et al. (2011) Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 10:292-306.
27. Richards DB, Walker GA, Mandagere A, Magee MH, and Henderson LS (2009) Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol 49:719-724.
28. Riechers H, Albrecht HP, Amberg W, Baumann E, Bernard H, Böhm HJ, Klinge D, Kling A, Müller S, Raschack M, et al. (1996) Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem 39:2123-2128.
29. Rodrigues AV, Rollison HE,Martin S, Sarda S, Schulz-Utermoehl T, Stahl S, Gustafsson F, Eakins J, Kenna JG, and Wilson ID (2013) In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid. Arch Toxicol 87: 1569-1579.
30. Scott LJ (2007) Sitaxentan: in pulmonary arterial hypertension. Drugs 67:761-770, discussion 771-772.
31. Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, and Kenna JG (2011) Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 192:65-71.
32. Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, et al. (2012) In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 25: 1616-1632.
33. Wu C, Chan MF, Stavros F, Raju B, Okun I, Mong S, Keller KM, Brock T, Kogan TP, and Dixon RA (1997) Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 40:1690-1697.
34. Yuan L and Kaplowitz N (2013) Mechanisms of drug-induced liver injury. Clin Liver Dis 17:507-518, vii.